In Vivo Cardioprotection by N-Acetylcysteine and Isosorbide 5-Mononitrate in a Rat Model of Ischemia-Reperfusion

Laura Calvillo, Serge Masson, Monica Salio, Loredana Pollicino, Noeleen De Angelis, Fabio Fiordaliso, Antonio Bai, Pietro Ghezzi, Francesco Santangelo, Roberto Latini

Research output: Contribution to journalArticle

15 Citations (Scopus)

Abstract

Aims: We evaluated the effect of N-acetylcysteine (NAC, infused i.v.), isosorbide 5-mononitrate (IS5MN, by gavage), or their combination on cardiac injury in an in vivo rat model of 30-min ischemia followed by 24 hours or 7 days of reperfusion. Results: When administered immediately prior to reperfusion with continuous infusion for 24 h, the combination of NAC +IS5MN reduced infarct size (29 ± 6 vs. 59 ± 4% area-at-risk, p <0.01) and the infiltration of polymorphonuclear leukocytes (226 ± 15 vs. 315 ± 18 cells mm-2 of area-at-risk, p = 0.002) and monocytes/macrophages (118 ± 8 vs. 194 ± 22 cells mm -2, p = 0.012), compared to vehicle. NAC or IS5MN alone did not reduce infarct size at 24 hours of reperfusion. The same dose regimen of NAC and IS5MN did not reduce infarct size with permanent ischemia for 24 hours not followed by reperfusion. After 7 days of reperfusion (3 days of treatment with NAC +IS5MN or vehicle and 4 days of wash-out), infarct size was similar in the vehicle and NAC +IS5MN groups, but LV end-diastolic pressure and diastolic LV chamber wall stress were significantly lower in the animals treated with NAC +IS5MN (5 ± 1 mmHg and 62 ± 7 dyne mm-2, respectively) compared to vehicle (9 ± 1 mmHg and 123 ± 18 dyne mm -2, p <0.05). Conclusion: We demonstrate in a rat model of cardiac ischemia-reperfusion treated with NAC and IS5MN, according to a regimen that mimicked a clinical situation (drugs started at time of reperfusion), that the short-term benefit seen after 24 h of reperfusion (51% reduction of infarct size) is maintained after one week, possibly through modulation of the inflammatory response to cardiac injury.

Original languageEnglish
Pages (from-to)199-208
Number of pages10
JournalCardiovascular Drugs and Therapy
Volume17
Issue number3
DOIs
Publication statusPublished - 2003

Fingerprint

isosorbide-5-mononitrate
Acetylcysteine
Reperfusion
Ischemia
Wounds and Injuries
Monocytes

Keywords

  • Antioxidant
  • Heart
  • Infarct size
  • Ischemia/reperfusion injury
  • Isosorbide 5-mononitrate
  • N-acetylcysteine
  • Rat

ASJC Scopus subject areas

  • Pharmacology (medical)
  • Cardiology and Cardiovascular Medicine
  • Pharmacology

Cite this

In Vivo Cardioprotection by N-Acetylcysteine and Isosorbide 5-Mononitrate in a Rat Model of Ischemia-Reperfusion. / Calvillo, Laura; Masson, Serge; Salio, Monica; Pollicino, Loredana; De Angelis, Noeleen; Fiordaliso, Fabio; Bai, Antonio; Ghezzi, Pietro; Santangelo, Francesco; Latini, Roberto.

In: Cardiovascular Drugs and Therapy, Vol. 17, No. 3, 2003, p. 199-208.

Research output: Contribution to journalArticle

Calvillo, Laura ; Masson, Serge ; Salio, Monica ; Pollicino, Loredana ; De Angelis, Noeleen ; Fiordaliso, Fabio ; Bai, Antonio ; Ghezzi, Pietro ; Santangelo, Francesco ; Latini, Roberto. / In Vivo Cardioprotection by N-Acetylcysteine and Isosorbide 5-Mononitrate in a Rat Model of Ischemia-Reperfusion. In: Cardiovascular Drugs and Therapy. 2003 ; Vol. 17, No. 3. pp. 199-208.
@article{6f3b9df7b6dc4fa898300f5a641d9089,
title = "In Vivo Cardioprotection by N-Acetylcysteine and Isosorbide 5-Mononitrate in a Rat Model of Ischemia-Reperfusion",
abstract = "Aims: We evaluated the effect of N-acetylcysteine (NAC, infused i.v.), isosorbide 5-mononitrate (IS5MN, by gavage), or their combination on cardiac injury in an in vivo rat model of 30-min ischemia followed by 24 hours or 7 days of reperfusion. Results: When administered immediately prior to reperfusion with continuous infusion for 24 h, the combination of NAC +IS5MN reduced infarct size (29 ± 6 vs. 59 ± 4{\%} area-at-risk, p <0.01) and the infiltration of polymorphonuclear leukocytes (226 ± 15 vs. 315 ± 18 cells mm-2 of area-at-risk, p = 0.002) and monocytes/macrophages (118 ± 8 vs. 194 ± 22 cells mm -2, p = 0.012), compared to vehicle. NAC or IS5MN alone did not reduce infarct size at 24 hours of reperfusion. The same dose regimen of NAC and IS5MN did not reduce infarct size with permanent ischemia for 24 hours not followed by reperfusion. After 7 days of reperfusion (3 days of treatment with NAC +IS5MN or vehicle and 4 days of wash-out), infarct size was similar in the vehicle and NAC +IS5MN groups, but LV end-diastolic pressure and diastolic LV chamber wall stress were significantly lower in the animals treated with NAC +IS5MN (5 ± 1 mmHg and 62 ± 7 dyne mm-2, respectively) compared to vehicle (9 ± 1 mmHg and 123 ± 18 dyne mm -2, p <0.05). Conclusion: We demonstrate in a rat model of cardiac ischemia-reperfusion treated with NAC and IS5MN, according to a regimen that mimicked a clinical situation (drugs started at time of reperfusion), that the short-term benefit seen after 24 h of reperfusion (51{\%} reduction of infarct size) is maintained after one week, possibly through modulation of the inflammatory response to cardiac injury.",
keywords = "Antioxidant, Heart, Infarct size, Ischemia/reperfusion injury, Isosorbide 5-mononitrate, N-acetylcysteine, Rat",
author = "Laura Calvillo and Serge Masson and Monica Salio and Loredana Pollicino and {De Angelis}, Noeleen and Fabio Fiordaliso and Antonio Bai and Pietro Ghezzi and Francesco Santangelo and Roberto Latini",
year = "2003",
doi = "10.1023/A:1026182404805",
language = "English",
volume = "17",
pages = "199--208",
journal = "Cardiovascular Drugs and Therapy",
issn = "0920-3206",
publisher = "Kluwer Academic Publishers",
number = "3",

}

TY - JOUR

T1 - In Vivo Cardioprotection by N-Acetylcysteine and Isosorbide 5-Mononitrate in a Rat Model of Ischemia-Reperfusion

AU - Calvillo, Laura

AU - Masson, Serge

AU - Salio, Monica

AU - Pollicino, Loredana

AU - De Angelis, Noeleen

AU - Fiordaliso, Fabio

AU - Bai, Antonio

AU - Ghezzi, Pietro

AU - Santangelo, Francesco

AU - Latini, Roberto

PY - 2003

Y1 - 2003

N2 - Aims: We evaluated the effect of N-acetylcysteine (NAC, infused i.v.), isosorbide 5-mononitrate (IS5MN, by gavage), or their combination on cardiac injury in an in vivo rat model of 30-min ischemia followed by 24 hours or 7 days of reperfusion. Results: When administered immediately prior to reperfusion with continuous infusion for 24 h, the combination of NAC +IS5MN reduced infarct size (29 ± 6 vs. 59 ± 4% area-at-risk, p <0.01) and the infiltration of polymorphonuclear leukocytes (226 ± 15 vs. 315 ± 18 cells mm-2 of area-at-risk, p = 0.002) and monocytes/macrophages (118 ± 8 vs. 194 ± 22 cells mm -2, p = 0.012), compared to vehicle. NAC or IS5MN alone did not reduce infarct size at 24 hours of reperfusion. The same dose regimen of NAC and IS5MN did not reduce infarct size with permanent ischemia for 24 hours not followed by reperfusion. After 7 days of reperfusion (3 days of treatment with NAC +IS5MN or vehicle and 4 days of wash-out), infarct size was similar in the vehicle and NAC +IS5MN groups, but LV end-diastolic pressure and diastolic LV chamber wall stress were significantly lower in the animals treated with NAC +IS5MN (5 ± 1 mmHg and 62 ± 7 dyne mm-2, respectively) compared to vehicle (9 ± 1 mmHg and 123 ± 18 dyne mm -2, p <0.05). Conclusion: We demonstrate in a rat model of cardiac ischemia-reperfusion treated with NAC and IS5MN, according to a regimen that mimicked a clinical situation (drugs started at time of reperfusion), that the short-term benefit seen after 24 h of reperfusion (51% reduction of infarct size) is maintained after one week, possibly through modulation of the inflammatory response to cardiac injury.

AB - Aims: We evaluated the effect of N-acetylcysteine (NAC, infused i.v.), isosorbide 5-mononitrate (IS5MN, by gavage), or their combination on cardiac injury in an in vivo rat model of 30-min ischemia followed by 24 hours or 7 days of reperfusion. Results: When administered immediately prior to reperfusion with continuous infusion for 24 h, the combination of NAC +IS5MN reduced infarct size (29 ± 6 vs. 59 ± 4% area-at-risk, p <0.01) and the infiltration of polymorphonuclear leukocytes (226 ± 15 vs. 315 ± 18 cells mm-2 of area-at-risk, p = 0.002) and monocytes/macrophages (118 ± 8 vs. 194 ± 22 cells mm -2, p = 0.012), compared to vehicle. NAC or IS5MN alone did not reduce infarct size at 24 hours of reperfusion. The same dose regimen of NAC and IS5MN did not reduce infarct size with permanent ischemia for 24 hours not followed by reperfusion. After 7 days of reperfusion (3 days of treatment with NAC +IS5MN or vehicle and 4 days of wash-out), infarct size was similar in the vehicle and NAC +IS5MN groups, but LV end-diastolic pressure and diastolic LV chamber wall stress were significantly lower in the animals treated with NAC +IS5MN (5 ± 1 mmHg and 62 ± 7 dyne mm-2, respectively) compared to vehicle (9 ± 1 mmHg and 123 ± 18 dyne mm -2, p <0.05). Conclusion: We demonstrate in a rat model of cardiac ischemia-reperfusion treated with NAC and IS5MN, according to a regimen that mimicked a clinical situation (drugs started at time of reperfusion), that the short-term benefit seen after 24 h of reperfusion (51% reduction of infarct size) is maintained after one week, possibly through modulation of the inflammatory response to cardiac injury.

KW - Antioxidant

KW - Heart

KW - Infarct size

KW - Ischemia/reperfusion injury

KW - Isosorbide 5-mononitrate

KW - N-acetylcysteine

KW - Rat

UR - http://www.scopus.com/inward/record.url?scp=10744228762&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=10744228762&partnerID=8YFLogxK

U2 - 10.1023/A:1026182404805

DO - 10.1023/A:1026182404805

M3 - Article

C2 - 14574078

AN - SCOPUS:10744228762

VL - 17

SP - 199

EP - 208

JO - Cardiovascular Drugs and Therapy

JF - Cardiovascular Drugs and Therapy

SN - 0920-3206

IS - 3

ER -